RPG Life Sciences Limited (IN:RPGLIFE)
:RPGLIFE
Top Page
RPG Life Sciences Limited
(RPGLIFE)
Select Model
Select Model
Rating:76Outperform
Price Target:
₹2,139.00
▼(-7.14% Downside)
Action:N/ADate:01/04/26
The score is driven primarily by strong financial performance—high and improving margins and a near debt-free balance sheet—tempered by weaker cash-flow conversion versus reported earnings. Technical signals are broadly neutral, and valuation looks reasonable on P/E but with a modest dividend yield.
Positive Factors
Margin Expansion
Sustained high gross margins and a large rise in net margin indicate durable pricing power and operating leverage from branded formulations. Over the medium term this supports strong internal cash generation, higher returns on equity and the ability to reinvest in sales and R&D without relying on external financing.
Negative Factors
Weak Cash Conversion
Earnings outpacing cash suggests working-capital needs or accrual-driven profits, reducing available free cash for capex, dividends or debt reduction. Over time, inconsistent cash conversion can constrain organic investment and make the company more sensitive to collection or inventory shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Margin Expansion
Sustained high gross margins and a large rise in net margin indicate durable pricing power and operating leverage from branded formulations. Over the medium term this supports strong internal cash generation, higher returns on equity and the ability to reinvest in sales and R&D without relying on external financing.
Read all positive factors
RPG Life Sciences Limited (RPGLIFE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹31.31B
Dividend Yield0.85%
Average Volume (3M)3.23K
Price to Earnings (P/E)43.4
Beta (1Y)0.73
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees1,270
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)13.38
Shares Outstanding16,539,015
10 Day Avg. Volume8,652
30 Day Avg. Volume3,228
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)7.03
Price to Sales (P/S)5.71
P/FCF Ratio89.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹2,470.00Price Target Upside7.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RPG Life Sciences Limited Business Overview & Revenue Model
Company Description
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic A...
How the Company Makes Money
RPGLIFE makes money primarily by selling pharmaceutical formulations (finished dosage medicines) under its own brands. Revenue is generated when its field force and channel network (stockists/distributors and pharmacies/hospitals) sell these produ...
RPG Life Sciences Limited Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
94
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.66B | 6.53B | 5.77B | 5.09B | 4.37B | 3.83B |
| Gross Profit | 3.94B | 4.39B | 3.93B | 1.70B | 2.87B | 2.46B |
| EBITDA | 1.73B | 1.60B | 1.36B | 1.08B | 902.40M | 718.40M |
| Net Income | 2.15B | 1.83B | 876.60M | 676.40M | 514.80M | 400.00M |
Balance Sheet | ||||||
| Total Assets | 7.06B | 6.58B | 5.13B | 4.19B | 3.45B | 3.03B |
| Cash, Cash Equivalents and Short-Term Investments | 2.24B | 2.66B | 1.26B | 1.15B | 698.00M | 403.60M |
| Total Debt | 0.00 | 0.00 | 0.00 | 100.00K | 9.40M | 20.20M |
| Total Liabilities | 1.52B | 1.27B | 1.38B | 1.12B | 888.40M | 869.40M |
| Stockholders Equity | 5.54B | 5.31B | 3.75B | 3.08B | 2.56B | 2.16B |
Cash Flow | ||||||
| Free Cash Flow | -207.00M | 418.30M | 251.30M | 580.90M | 408.00M | 497.60M |
| Operating Cash Flow | 112.70M | 778.60M | 943.60M | 908.20M | 647.50M | 582.70M |
| Investing Cash Flow | 206.70M | -418.00M | -791.50M | -1.06B | -346.60M | -79.60M |
| Financing Cash Flow | -399.40M | -270.80M | -203.10M | -171.20M | -135.10M | -104.90M |
RPG Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹31.31B | 43.39 | ― | 0.85% | ― | ― | |
61 Neutral | ₹23.89B | 2.94 | ― | ― | 25.42% | ― | |
57 Neutral | ₹32.38B | 23.17 | ― | 0.24% | 4.08% | 31.52% | |
57 Neutral | ₹30.21B | 67.80 | ― | 0.03% | 7.78% | -34.68% | |
57 Neutral | ₹21.69B | 20.54 | ― | 0.49% | -0.29% | -29.04% | |
54 Neutral | ₹28.36B | -76.20 | ― | ― | -9.23% | -56.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:RPGLIFE
RPG Life Sciences Limited
1,893.15
-150.51
-7.36%
IN:AARTIDRUGS
Aarti Drugs Limited
354.75
27.45
8.39%
IN:GUFICBIO
Gufic Biosciences Limited
301.20
-28.91
-8.76%
IN:MOREPENLAB
Morepen Laboratories Limited
40.18
-9.80
-19.61%
IN:ORCHPHARMA
Orchid Pharma Limited
559.20
-160.20
-22.27%
IN:UNICHEMLAB
Unichem Laboratories Limited
339.35
-229.00
-40.29%
RPG Life Sciences Limited Corporate Events
RPG Life Sciences to Close Trading Window Ahead of FY26 Results
Mar 24, 2026
RPG Life Sciences Limited has announced that its trading window for dealing in the company’s securities by designated persons and their immediate relatives will be closed from April 1, 2026. The restriction will remain in place until 48 hour...
RPG Life Sciences Board Clears Q3 and Nine-Month FY26 Unaudited Results
Jan 27, 2026
RPG Life Sciences Limited has announced that its Board of Directors, at a meeting held on 27 January 2026, approved the company’s unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025....
RPG Life Sciences Posts Steady Q3 FY26 Growth With Robust Margins
Jan 27, 2026
RPG Life Sciences reported a 4.2% year-on-year rise in revenue to Rs 180 crore for the third quarter ended 31 December 2025, with an EBITDA margin of 24%, while nine-month FY26 revenue grew 4% to Rs 530.6 crore, underscoring steady operational mom...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.